"One week Jun" domestic and foreign pharmaceutical companies bull pile exposure semi-annual report; Sichuan Peoplefu was sold; Tag Pharmaceuticals into the domestic third A-H listed CRO enterprises; this year's health insurance catalog adjustment started.

Guide: Compared with the performance of Chinese and foreign pharmaceutical enterprises, transnational groups are the more difficult to bridge the gap between Chinese pharmaceutical companies.
.The week's top-profile pharmaceutical companies are stacked with half-yearly reports; 2.Sichuan Renfu Pharmaceutical Co., Ltd. is sold; 3. Tyger Pharma becomes the third Domestic A-H-listed CRO company; 4.This year's health insurance catalog adjustment starts; AstraZeneca: China's market grew 14 percent in the first half of 2020 July 30, British pharmaceutical giant AstraZeneca reported first half-year results, with global revenue of $12.229 billion.
are derived mainly from the performance of new products in emerging markets and the oncology sector.
total sales revenue of $12.359 billion, up 13% year-on-year.
first half of the year, AstraZeneca's oncology products revenue was $5.324 billion, up 31% YoY, while Cardiovascular, Kidney and Metabolism (CVRM) products were $2.265 billion, up 11% YoY, and respiratory and immunology products were $2.676 billion, up 7% YoY.
AstraZeneca's global revenue was $6 billion in the second quarter, up 9 percent from a year earlier.
, but revenues from respiratory and immunology products fell 8 percent, mainly because of the impact of the new corona pneumonia outbreak on the sales of Pumedubao (Budined) in China.
by product: The main core drivers of oncology products include the non-small cell lung cancer treatment drug Terissa, with sales of US$2.016 billion, up 45% YoY;PD-L1 single anti-Infifan sales reached US$954 million, up 52%; The treatment drug Liptro sales were $816 million, up 60 percent year-on-year, while other chronic leukemia treatment leukemia, with sales of $195 million, and Enhertu, an antibody-conjugate dispensing drug, was split into $36 million.
Mercado: Total revenue in the second quarter was $10.9 billion, k-drug sold $3.4 billion! Mercado recently reported second-quarter 2020 results of $10.9 billion, down 8% year-on-year, excluding foreign exchange, global sales fell 5%.
pharmaceutical business revenue of $9.7 billion, down 7% year-on-year, while sales fell 6 percent, excluding foreign exchange adverse effects.
most notable, the main reasons for the decline in the company's pharmaceutical business were the negative impact of the outbreak on vaccines and hospital emergency care products, as well as the continuing impact of the loss of market ownership for some products, which were partially offset by strong growth in the oncology business. Keytruda's sales rose 29 percent to $3.4 billion in the
oncology business, driven by the continued strength of non-small cell lung cancer adaptation and the continued absorption of other indications, including assisted treatments for melanoma, kidney cell carcinoma, bladder cancer, head and neck cancer, and hypercomputerinstability (MSI-H) cancers.
high co-op revenues associated with Lynparza and Lenvima also contributed to the growth of the oncology business, reflecting continued market penetration of approved indications in the U.S., Europe and China.
Hengrui: five-year revenue growth fell below 20%, research and development investment against the trend of 25% on August 1, Hengrui Pharmaceuticals announced the 2020 semi-annual report, from the total revenue and net profit to see Hengrui still maintain the top position of domestic biopharmaceutical enterprises, but compared with the growth rate of the same period last year, the impact of the new crown epidemic is very prominent. according to the
statement, Hengrui Pharmaceuticals' total first-half revenue was RMB11,309 million, up 12.79 percent from RMB10,026 million in the same period in 19;
even if half a year to achieve 10 billion revenue, but Hengrui still can not escape the impact of the new crown epidemic.
total revenue of Hengrui increased by 12.79% YoY in the first half of the year, while in the last five years, hengrui Pharmaceuticals' total revenue increased by 29.19% YoY in the 2019 Half Year Report, 22.32% YoY in 2018, 20.18% YoY in 2017, 20.35% YoY in 2016 and 24.95% YoY in 2015.
can be seen that for five years Hengrui Pharmaceuticals has maintained an annual growth rate of more than 20% in the first half of the year, and continues to grow after 2017.
it can be seen that the impact of the new crown outbreak on the growth of Hengrui has a negative impact.
Beida Pharmaceuticals: Ektini's first-half sales of 924 million yuan On August 5, Beida Pharmaceuticals announced its first-half results for 2020, with operating income of 952 million yuan, up 24.92 percent year-on-year, and net profit attributable to common shareholders of listed companies was 144 million yuan, up 64.65 percent year-on-year, and net profit attributable to shareholders of listed companies after non-recurring profit and loss was 141 million yuan.
, Ektini continued to grow at a high rate in the first half of the year, with sales of 924 million yuan.
also reported that as of the end of the reporting period, Ektinib has benefited more than 250,000 patients with advanced lung cancer, of which 1,600 patients who took Ektinib for more than five years, with cumulative sales exceeding 8 billion yuan.
Bayer: Revenue from winning bids fell 74% On August 4, Bayer reported a 6.2% decline in revenue of EUR 10,054 million, and revenue of EUR 22.899 billion, down 0.3% in the first half of the year.
, the pharmaceutical business was affected by COVID-19 and China's volume purchasing policy, with revenues falling 8.8 percent to EUR 3,992 million in the second quarter.
in the Chinese market, Bayer diabetes drug Glucoba (Acapo sugar, by sugar) in the second batch of national collection of 0.181 yuan / tablet of the successful bid, a decline of 91.56 percent. according to the
's second-quarter results, global sales fell 74.2 percent to just 40 million euros in the second quarter, while cumulative sales fell 54.4 percent to 156 million euros in the first half of the year.
Regenerative Yuan: Second Quarter Results bucked the trend of 24% Eylea, Dupixent credit! On August 5, Regeneron reported second-quarter 2020 results of $1.95 billion, up 24% year-on-year, up from $1.74 billion previously expected.
GAAP Diluted Earnings per Share (EPS) was $7.61 and non-GAAPEPS was $7.16.
, Eylea's net sales in the U.S. market, which were severely affected by the outbreak, were $1.114 billion ($1.16 billion a year earlier), up 4 percent from a year earlier, but still beating expectations.
sales of rival lucentis fell 25 per cent over the same period.
Eylea excelled across the entire anti-VEGF sector, with a growing market share and now accounting for 73% of the U.S. market share of branded pharmaceuticals.
in fact, Eylea's sales have been picking up since May as medical experts redevelop their offices and patient numbers, and its 12-week flexible feeding interval is a valuable feature of treating patients during the pandemic.
's global net sales of the anti-inflammatory drug Dupixent reached $945 million (recorded by Sanofi), beating the consensus estimate of 4 percent, driven mainly by the U.S. market.
anti-PD-1 treatment Libtayo also beat industry expectations, with global sales of $80 million in the second quarter.
recently, Libtayo significantly extended total survival compared to chemotherapy in a phase III clinical trial for first-line treatment of non-small cell lung cancer.
Regeneration Dollar has plans to submit a new indication application in the United States.
Baiji Shenzhou: Revenue reached a new high of 66 million in the second quarter of 2020, and Baiji Shenzhou announced its recent business highlights, expected milestones and financial results for the second quarter and first half of 2020.
"We have come a long way since the second quarter, when we were approved for three indications in the ® of Bazean ® and Bai Yueze, and eight new drug listings were accepted in China, the European Union, Australia and Israel, ®, Bacau zeaze ® and Pamipali.
revenue hit a new high of about $66 million in the quarter, driven by the company's commercialization team, mainly from our recently launched independent research and development products. Mr. o'Reilly,
," added Mr. O'Reilly, "The company's recent successful direct issuance of a net income of approximately $2.07 billion will significantly accelerate the development of existing rich research and development pipelines, further expand our portfolio in the field of oncology and other diseases, and continue to build in-house capabilities and operations to serve more patients worldwide."
for the rest of 2020 and 2021, we look forward to expanding the business opportunities of our products by being approved in new indications and geographic markets and increasing our business phase portfolio to 11.
"Ali Health: Fund-raising at a discount!" How does the Internet Medical Profit Model Break? On August 5, Ali Health announced that it had entered into an placement agreement with placement agents Citi Global Financial Limited and Credit Suisse (Hong Kong) Limited to place a total of 499 million new shares at a price of HK$20.05 per share, representing approximately 3.71% of the enlarged issued share capital.
the public offering was discounted by about 8.03 per cent, by the closing price of Ali Health on August 4th, HK$21.8.
First Sound Pharmaceuticals: $170 million to introduce a CDK4/6 Inhibitor Greater China Equity August 3, 2020, North Carolina, USA and Nanjing, China, Clinical Stage Oncology Company G1Therapeutics, Inc. (NASDAQ stock code: GTH X) and China First Voice Pharmaceuticals announced an exclusive license agreement for the development and commercialization of the injectable CDK4/6 inhibitor Trilaciclib in all parts of Greater China (Chinese mainland, Hong Kong, Macau and Taiwan) after China rapidly transformed itself into an innovation and research-led company.
trilaciclib, discovered and developed by G1, is a leading research therapy designed to improve the prognosis of cancer patients treated with chemotherapy.
is currently listed in the queue for the hong Kong stock market of the first sound pharmaceutical industry, and is expected to pass the hearing soon.
(G1 and BI are selling Trilaclib in the United States and Puerto Rico.
AstraZeneca and Conte Bio agreed to a contract on the new crown vaccine AstraZeneca today announced the signing of an exclusive licensing cooperation agreement with Conte Bio Chinese mainland Market to actively promote the development, production, supply and commercialization of Aadenergy's new adenovirus vector AZD1222 in the Chinese mainland market through technology transfer.
future, the two sides will continue to explore the possibility of cooperation between the vaccine in other regions and markets.
move is expected to bring the world's leading vaccine technology to China at the global level, benefiting Chinese people as soon as possible.
this is also AstraZeneca's active commitment to corporate social responsibility, adhere to the "in China, for China" long-term commitment to a strong action.
Sichuan Renfu Pharmaceutical Co., Ltd. was sold on August 5, Renfu Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Renfu Pharmaceuticals") announced that it intends to transfer its 70% stake in Sichuan Renfu Pharmaceutical Co., Ltd. to Chongqing Pharmaceuticals (Group) Co., Ltd. ("Heavy Pharmaceutical Group") for 362 million yuan.
is understood that heavy pharmaceutical group is based on pharmaceutical business, pharmaceutical research and development of cooperative development of enterprises, is the central and Chongqing two-level drug medical equipment fixed-point reserve units, but also operating narcotic drugs and the first class of psychotropic drugs of the national wholesale enterprises.
as of December 31, 2019, the total assets of the heavy pharmaceutical group were RMB2483,276 million, net assets of RMB734.459 million, and the company achieved operating income of RMB33.84 billion and net profit of RMB930 million for the 2019 fiscal year.
and Sichuan Renfu is a hospital drug sales, commercial distribution, medical equipment supplies sales and other business in one integrated pharmaceutical commercial company, the company under the jurisdiction of more than 10 holding subsidiaries, basically covering all levels of medical and health institutions in Sichuan Province.
Tag Pharma H-share offering price: HK$100/share offering hk$10.7 billion on August 3, Tyger Pharma announced that it has decided to list on the main board of the Hong Kong Stock Exchange on August 7, 2020, with the final price of the issue of overseas listed foreign shares (H-shares) at HK$100.00/share.
as of July 31, the company's subscription has recorded $91.25 billion, about 154 times oversubscribed.
it is understood that the IPO is intended to issue 107 million new shares, accounting for 12.5% of the total number of shares after the issue, the proposed capital raising of HK$10.7 billion, by Merrill Lynch Far East, Haitong International, CITIC Lyon and CICC Hong Kong as co-sponsors of the company.
, if successfully listed, will become the largest IPO of an Asian biopharmaceutical company so far this year, and will also become the third domestic CRO company to list in China after the drug Mingkang and Kanglong.
this year's health care directory adjustment started! To add 7 new types of drugs! On August 3rd, the State Health Insurance Administration (NSS) issued the Work Programme for the Adjustment of the National Medical Insurance Drug Catalog for 2020 (the "Draft for Comments"), which will be available for comments by August 10, 2020.
the draft of the opinions clearly, in accordance with the "Temporary Measures for the Administration of Drug Use in Basic Medical Insurance" articles 7 and 8, and with one of the following circumstances, drugs outside the list of drugs, may be included in the 2020 National Basic Medical Insurance Drug Catalog (hereinafter referred to as the Drug Catalog) to add the scope of new drugs.
1. Medication for the treatment of respiratory diseases associated with xinguan pneumonia.
2. Drugs included in the National Essential Medicines List (2018 edition).
3. Include in the list of new drugs abroad that are urgently needed in clinical areas, encourage the list of generic drugs, or encourage research and development to declare the list of children's medicines, and approve the listing of drugs by the State Drug Administration by 31 December 2019.
4. The second batch of state-organized drugs are centrally procured.
5. January 2015 to December 2019.